Crystal structure and conformation of 5-fluorouridine: Conformational preferences for 5-fluorinated pyranosides

Nucleosides, Nucleotides and Nucleic Acids

Volumn 23, Issue 11, 2004, Pages 1779-1795

  Soni, Sunil Dutta ^a   Srikrishnan, Thamarapu ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Conformational preferences; Fluoropyrimidines; Structure activity relationships

Indexed keywords

5 FLUORINATED PYRANOSIDE; FLUORINE; FLUOROURACIL; FLUOROURIDINE; NUCLEOSIDE DERIVATIVE; OXYGEN; PYRANOSIDE; UNCLASSIFIED DRUG; URACIL;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL BOND; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIFFRACTION; DRUG CONFORMATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROGEN BOND; MOUSE; NONHUMAN; RELIABILITY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; CRYSTALLOGRAPHY, X-RAY; HELA CELLS; HUMANS; HYDROGEN BONDING; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; URIDINE;

ANIMALIA;

EID: 9644260501     PISSN: 15257770     EISSN: None     Source Type: Journal    
DOI: 10.1081/NCN-200034052     Document Type: Article

References (63)

1. Dunn, D.B.; Smith, J.D.; Zamenhof, S.; Griboff, G. Incorporation of halogenated pyrimidines into the deoxyribonucleic acids of Bacterium coli and its bacteriophages. Nature 1954, 174, 305-306.
2. Zammenhof, S.; Griboff, G.; Marullo, N. Studies on the resistance of desoxyribonucleic acids to physical and chemical factors. Biochim. Biophys. Acta 1954, 13, 459-470.
3. Rutman, R.J.; Cantrow, A.; Paschkis, K.E. Studies in 2- acetylaminofluorene carcinogenesis. III. The utilization of uracil-2-C14 by preneoplastic rat liver and rat hepatoma. Cancer Res. 1954, 14, 119-123.
4. Heidelberger, C.; Chaudhri, N.K.; Dannenerg, P.; Mooren, D.; Griesbach, L.; Duschinsky, R.; Schnitzer, R.J.; Pleven, E.; Schneier, J. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957, 179, 663-666.
5. Houghton, J.A.; Houghton, P.J.; Wooten, R.S. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine and 5-fluoro-2-deoxyuridine. Cancer Res. 1979, 39, 2406-2413.
6. Machover, D.; Schwarzenberg, L.; Goldschmidt, E.; Tourani, J.M.; Michalski, B.; Hayat, M.; Dorval, T.; Misset, J.L.; Jasmin, C.; Maral, R.; Mathe, G. Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study. Cancer Treat. Rep. 1982, 66, 1803-1807.
7. Danzi, M.; Lewin, M.R.; Cruse, J.P.; Clark, C.G. Combination chemotherapy with 5-fluorouracil (5FU) and 1 ,3-bis(2-chloro-ethyl)-1-nitrosourea (BCNU) prolongs survival of rats with dimethylhydrazine-induced colon cancer. Gut 1983, 24, 1041-1047.
8. Cunningham, J.; Bukowski, R.M.; Budd, G.T.; Weick, J.K.; Purvis, J. 5-Fluorouracil and folinic acid: a phase I-II trial in gastrointestinal malignancy. Invest. New Drugs 1984, 2, 391-395.
9. Perez, J.E.; Macchiavelli, M.; Leone, B.A.; Romero, A.; Rabinovich, M.G.; Arevalo, E.; Strauss, E. Treatment of advanced stomach carcinoma with adriamycin and 5-fluorouracil. Acta Gastroenterol. Latinoam. 1984, 14, 63-72.
10. Hirono, M.; Niimoto, M.; Toge, T.; Hattori, T.; Oride, M.; Nakajima, T.; Hirata, K.; Kimura, T.; Nakazato, H.; Iwanaga, T. A cohort study on second malignancies in gastrectomized patients with gastric cancer. I. Second malignancies other than cancer of the gastric remnant. Jpn. J. Surg. 1986, 16, 336-343.
11. Kleinmanns, G.; Daver, W.; Knief, J.J.; Westerhausen, M. Therapeutic results in advanced ovarian cancer. Onkologie 1983, 6, 206-209.
12. Dasmahapatra, K.S.; Citrin, P.; Hill, G.J.; Yee, R.; Mohit-Tabatabai, M.A.; Rush, B.F., Jr. A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck. J. Clin. Oncol. 1985, 3, 1486-1489.
13. Reshad, K.; Inui, K.; Takeuchi, Y.; Takahashi, Y.; Hitomi, S. Treatment of malignant pleural effusion. Chest 1985, 88, 393-400.
14. Chobra, T.; Orenstein, J.M.; Harisiadis, L.; Moody, T.; Burton, T.; Schulof, R.S. An atypical endocrine tumor of the lung responsive to radiation therapy and 5-fluorouracil-streptozotocin. Cancer 1984, 53, 2430-2436.
15. Smalley, R.V.; Bartolucci, A.A.; Moore, M.; Vogel, C.; Carpenter, J.; Perez, C.A.; Velez-Garcia, E.; Marcial, V.; Lefante, J.; Wittliff, J. Southeastern Cancer Study Group: breast cancer studies 1972-1982. Int. J. Radiat. Oncol. Biol. Phys. 1983, 9, 1867-1874.
16. Gebelein, C.G.; Glowacky, R. Chemotherapeutic polymers.2. Synthesis of some potentially polymerizable derivatives of 6-mercaptopurine. Polym. Prepr. 1977, 18, 806-812.
17. Gebelein, C.G.; Glowacky, R. Chemotherapeutic polymers.3. Synthesis of some polymerizable derivatives of 5-fluorouracil. Polym. Prepr. 1977, 18, 811-820.
18. Wilkinson, D.S.; Crumley, J. Metabolism of 5-fluorouracil insensitive and resistant Novikoff hepatoma cells. J. Biol. Chem. 1977, 252, 1051-1061.
19. Ardalan, B.; Cooney, D.A.; Jayaram, H.N.; Carrico, C.K.; Glazer, R.I.; Macdonald, J.; Schein, P.S. Mechanisms of sensitivity and resistance of murine tumors to 5-fluorouracil. Cancer Res. 1980, 40, 1431-1441.
20. Benefraim, S.; Shoval, S.; DeClerq, E. Enhancing effect of bromovinyldeoxyuridine on antitumor-activity of 5-fluorouracil in mice bearing MOPC-315 plasmacytomas. Br. J. Can. 1986, 54, 847-851.
21. Brodsky, I.; Strayer, D.R.; Gillespie, D.H. Platelet DNA polymerase: diagnostic significance in myeloproliferative disorders. Proc. Am. Cancer Res. 1981, C41.
22. Alderfer, J.L.; Soni, S.D.; Wallace, J.C.; Hazel, G.L. Fluorinated nucleic acids-sensitivity to light and photoproduct distribution. Biophys. J. 1988, 53, A484.
23. Germain, G.; Main, P.; Woolfson, M.M. The application of phase relationships to complex structures. III. The optimum use of phase relationships. Acta Crystallogr. 1976, A27, 368-376.
24. International Tables for X-ray Crystallography; Kynoch Press: Birmingham, 1974; Vol. IV, 72.
25. Johnson, C.K. ORTEP Report ORNL-3792; Oak Ridge National Laboratory, TN, 1965.
26. Harris, D.R.; Macintyre, W.M. The crystal and molecular structure of 5-fluro-2′-deoxy-beta-uridine. Biophys. J. 1964, 4, 203-225.
27. Falcon, L. The crystal structure of 5-fluorouracil. Acta Crystallogr. 1973, 27, 2549-2559.
28. Parry, G.S. The crystal structure of uracil. Acta Crystallogr. 1954, 7, 313-323.
29. Soni, S.D.; Srikrishnan, T.; Alderfer, J.L. Halogenated nucleic acids: structure and conformational studies of 5-fluorocytidine by x-ray crystallography and NMR spectroscopy. Nucleosides Nucleotides Nucleic Acids 1996, 15, 1945-1958.
30. Altona, C.; Sundaralingam, M. Conformational analysis of the sugar ring in nucleosides and nucleotides. New description using the concept of pseudorotation. J. Am. Chem. Soc. 1977, 94, 8205-8210.
31. Altona, C.; Geise, H.J.; Romers, C. Conformation of non-aromatic ring compounds-XXV*1: geometry and conformation of ring D in steroids from x-ray structure determinations. Tetrahedron 1968, 24, 13-32.
32. Sundaralingam, M. Some aspects of stereochemistry and hydrogen bonding of carbohydrates related to polysaccharide conformations. Biopolymers 1968, 6, 189-213.
33. Bugg, CE.; Thomas, J.M.; Sundaralingam, M.; Rao, S.T. Stereochemistry of nucleic acids and their constituents. X. Solid-state base-stacking patterns in nucleic acid constituents and polynucleotides. Biopolymers 1971, 10, 175-219.
34. Hruska, F.E.; Wood, D.J.; Ogilvie, K.K.; Charlton, J.L. Proton magnetic-resonance study of ultraviolet photoproduct of d(TPT) in aqueous-solution. Can. J. Chem. 1975, 53, 1193-1203.
35. Davies, D.B.; Danyluk, S.S. Nuclear magnetic resonance studies of 5′-ribo- and deoxyribonucleotide structures in solution. Biochemistry 1974, 13, 4417-4434.
36. Soni, S.D. Ph.D. Dissertation; Roswell Park Division of SUNYAB: Buffalo, NY, 1989.
37. Kim, J.K.; Soni, S.D.; Wallace, J.C.; Alderfer, J.L. Solution structure of nucleic acid photoadduct, deoxy-m5HO6-uridylyl(5-5)(3′-5′) deoxyuridine by NMR and restrained molecular dynamics. Nucleic Acids Res. 1993, 21, 2755-2759.
38. Alderfer, J.L.; Soni, S.D.; Arakali, A.V.; Wallace, J.C. UV irradiation of nucleic acids: characterization of photoproducts of thymidylyl-(3′- >5)-2′-deoxy-5-fluorouridine. Photochem. Photobiol. 1993, 57, 770-776.
39. Kim, J.K.; Soni, S.D.; Arakali, A.V.; Wallace, J.C.; Alderfer, J.L. Solution structure of a nucleic acid photoproduct of deoxyfluorouridylyl- (3′-5′)-thymidine monophosphate (d-FpT) determined by NMR and restrained molecular dynamics: structural comparison of two sequence isomer photoadducts (d-U5p5T and d-T5pSU). Nucleic Acids Res. 1995, 23, 1810-1815.
40. Blokhina, N.G.; Vozny, E.K.; Garin, A.M. Results of treatment of malignant tumors with ftorafur. Cancer 1972, 30, 390-392.
41. Karev, N.I.; Blokhina, N.G.; Vozhy, E.K.; Pershin, M.P. Experience with ftorafur treatment in breast cancer. Neoplasma 1972, 19, 347-350.
42. 1-2′-furanidyl- S-fluorouraci). Cancer Res. 1976, 36, 1821-1824.
43. Cohen, A.M. The disposition of ftorafur in rats after intravenous administration. Drug Metab. Dispos. 1975, 3, 303-308.
44. 12′-tetrahydrofuryl-5-fluorouracil and 5-fluorouracul on nucleic acid and protein biosyntheses in Ehrlich Ascites cells. Cancer Res. 1976, 36, 33-36.
45. Smolyanskaya, A.Z.; Tugarinov, O.A. To biological activity of antitumour antimetabolite "Ftorafur." Neoplasma 1972, 19, 341-345.
46. Nakai, Y.; Yamamoto, K.; Terada, K.; Uchida, T.; Shimizu, N.; Nishigaki, S. The structure of Ftorafur. Chem. Pharm. Bull. (Japan) 1982, 30, 2629-2632.
47. Stokes, D.M.; Paul, B.; Alderfer, J.L.; Wollman, R.M.; Srikrishnan, T. Synthesis, structure and conformation of anti-tumor agents in the solis and solution states: hydroxyl derivatives of ftorafur. Nucleosides Nucleotides Nucleic Acids 2002, 21, 863-890.
48. Jarmula, A.; Anulewicz, R.; Les, A.; Cyranski, M.K.; Adamowicz, L.; Bretner, M.; Felczak, K.; Kulikowski, T.; Krygowski, T.M.; Rode, W. Crystal structures of 5-fluoro-durd and its 2 and/or 4-thio analogues: models of substituted dUMP pyrimidine ring interacting with thymidilete synthase. Biochim. Biophys. Acta 1998, 1382, 277-286.
49. Heidelberger, C.; Chaudhuri, N.K.; Danenberg, P.; Mooren, D.; Griesbach, L.; Duschinsky, R.; Schnitzer, R.J.; Pleven, E.; Schemer, J. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature (London) 1957, 179, 663-666.
50. Reyes, P.; Heidelberger, C. Fluorinated pyrimidines. XXVI. Mammalian thymidylate synthetase: its mechanism of action and inhibition by fluorinated nucleotides. Mol. Pharmacol. 1965, 1, 14-30.
51. Hartmann, K.; Heidelberger, C. Studies on fluorinated pyrimidines. XIII. Inhibition of thymidilate synthetase. J. Biol. Chem. 1965, 236, 3006-3013.
52. Wilkinson, D.S.; Crumley, J. Metabolism of 5-fluorouracil in sensitive and resistant Novikoff hepatoma cells. J. Biol. Chem. 1977, 252, 1051-1056.
53. Dolnick, B.J.; Pink, J.J. Effects of 5-fluorouracil on dihydrofolate reductase and dihydrofolate reductase mRNA from methotrexate-resistant KB cells. J. Biol. Chem. 1985, 260, 3006-3014.
54. Will, C.L.; Dolnick, B.J. 5-Fluorouracil augmentation of dihydrofolate reductase gene transcripts containing intervening sequences in methotrexate-resistant KB cells. Mol. Pharmacol. 1986, 29, 643-648.
55. Loomis, R.E. Ph.D. Dissertation; Roswell Park Division of SUNYAB: Buffalo, NY, 1985.
56. Duschinsky, R.; Pleven, E.; Heidelberger, C.J. The synthesis of 5-fluoropyrimidines. Am. Chem. Soc. 1957, 79, 4559-4560.
57. Heidelberger, C.; Danenberg, P.V.; Moran, R.G. Fluorinated pyrimidines and their nucleosides. Adv. Enzymol. Relat. Areas Mol. Biol. 1983, 54, 58-119.
58. Valeriote, F.; Santelli, G. 5-Fluorouracil (FUra). Pharmacol. Ther. 1984, 24, 107-132.
59. Chabner, B.A.; Myers, C.E. Cancer: Principles and Practice of Oncology; Lippincott Press: Philadelphia, 1989; 349-355.
60. Parker, W.B.; Cheng, Y.C. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol. Ther. 1990, 48, 381-395.
61. Valdiviseo, M.; Bodey, G.P.; Gottlieb, J.A.; Freireich, E.J. Clinical evaluation of ftorafur (pyrimidine-deoxyribose n1-2′-furanidyl-5- fluorouracil). Cancer Res. 1976, 36, 1821-1824.
62. Yasumoto, M.; Yamawaki, I.; Marunaka, T.; Hashimoto, S.J. Studies on antitumor agents, 1. Resolution of raccmic 1-(tetrahydro-2-furanyl)-5- fluorouracil into the R and S isomers and examination of the biological activities of the isomers. J. Med. Chem. 1977, 20, 1592-1594.
63. Yasumoto, M.; Yamawaki, I.; Marunaka, T.; Hashimoto, S.J. Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2- furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil. J. Med. Chem. 1978, 21, 738-741.